Treatments and therapies coverage from Pharma Journal: approved medicines, emerging options and the evidence behind them, and how new and established treatments reach patients.
In the SOLARIS trial, Weltruza lowered schizophrenia symptom scores by 9.75 to 11.27 points more than placebo at 8 weeks, with more weight gain and no peer-reviewed report yet. It is not approved in the UK or EU.
By Pharma Journal Editorial Desk, Editorial Desk
Only Bocouture holds an MHRA licence among Merz Aesthetics products; Belotero, Radiesse and Ultherapy are regulated as devices. Here is what that means.
By Dr. Eleanor Vance, Regulatory Affairs Editor
Biocon's pertuzumab biosimilar Pebrilzo has received a positive CHMP opinion — the first monoclonal antibody biosimilar under the EMA's tailored clinical development approach for HER2-positive breast cancer.
By Dr. Eleanor Vance, Regulatory Affairs Editor
The FDA has fully approved imlunestrant plus abemaciclib for ESR1-mutated ER-positive breast cancer, with EMBER-3 showing 11.1 vs 5.5 months PFS. Read on.
By Tom Okafor, Clinical Trials Correspondent
Long COVID symptoms can drag on for years. Learn what's driving them and how treatments like H.E.L.P. apheresis are being used to address the underlying causes.
By Tom Okafor, Clinical Trials Correspondent
For over a century, the discovery of insulin transformed Type 1 Diabetes (T1D) from a fatal diagnosis into a survivable condition. Yet, despite remarkable technological advances, patients remain tethe
By Dr. Eleanor Vance, Regulatory Affairs Editor
For patients living with blood cancer or a severe blood disorder, a stem cell transplant is often the turning point between decline and recovery. Yet for years in the UK, the calendar has been the ene
By Dr. Eleanor Vance, Regulatory Affairs Editor
Oral morphine sulphate supplied as Oramorph remains a first-line strong opioid when moderate to severe pain does not respond to weaker agents. The immediate release formulation supports fast onset, sh
By James Whitfield, Manufacturing & Supply Chain Writer
For acute pain, time matters. Patients with postoperative dental pain, primary dysmenorrhoea, tension-type headache or migraine want relief that begins quickly and remains reliable. Ibuprofen lysine,
By Dr. Eleanor Vance, Regulatory Affairs Editor
Huntington's disease remains without a cure in 2025. Clinical practice focuses on symptom control while a new wave of molecular programmes seeks to slow or halt neurodegeneration. The evidence base po
By Dr. Eleanor Vance, Regulatory Affairs Editor
Testosterone replacement therapy is widely requested, yet appropriate use depends on accurate diagnosis. True androgen deficiency is a clinical and biochemical syndrome. Symptoms must align with repea
By Tom Okafor, Clinical Trials Correspondent
Exposure and Response Prevention (ERP) sits at the centre of modern, evidence-based care for obsessive and anxiety-driven conditions. It is a structured behavioural method that asks people to face wha
By Tom Okafor, Clinical Trials Correspondent
Subscribe to our weekly pharmaceutical intelligence digest
We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy